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Background: In spite of the introduction of mild therapeutic hypothermia (MTH), mortality rates remain high in
patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA). To date, no accurate and independent
biomarker to predict survival in these patients exists. B-type natriuretic peptide (BNP) was found to provide both
prognostic and diagnostic value in various cardiovascular diseases, including survival to hospital discharge in patients
with ROSC. However, the biologically inactive counterpart of BNP, NT-proBNP, was found to be a more stable and
accurate analyte. The current retrospective observational study investigates the value of NT-proBNP to predict 28-day
mortality in post-CA patients treated with MTH, as well as the dynamics of NT-proBNP during MTH.
Methods: NT-proBNP levels were measured in post-CA patients cooled via cold intravenous saline infusion and water-
circulating body wraps (Medi-Therm®, Gaymar). Plasma samples were obtained before cooling was started, at the start
and end of the maintenance phase and at the end of rewarming.
Results: 250 patients, admitted between 2009 and 2013, had NT-proBNP levels measured on ICU admission and were
included for the evaluation of NT-proBNP as a prognostic marker. In the 28 days following ICU admission, 114 patients
died (46%). Non-survivors had significantly higher NT-proBNP (median 1448 ng/l, IQR 366–4623 vs median 567 ng/1,
IQR 148–1899; P < 0.001) levels on ICU admission. Unadjusted odds ratios for 28-day mortality were 1.7 (95% CI 0.8-3.5),
1.6 (0.8-3.3) and 3.6 (1.7-7.5) for increasing quartiles of NT-proBNP as compared to the lowest quartile. Adjusted odds
ratios were 1.1 (95% CI 0.5-2.5), 1.1 (0.5-2.5) and 1.6 (0.7-3.8), respectively. A cut-off value of 834 ng/l achieved a sensitivity
of 58% and a specificity of 58% to predict 28-day mortality. Of 113 patients, NT-proBNP values of each MTH phase were
available and grouped in decreased or increased levels in time. Both decreases and increases of NT-proBNP values were
observed during the MTH phases, but presence of either was not associated with outcome.
Conclusions: High NT-proBNP plasma concentrations on ICU admission are associated with high 28-day mortality in
post-CA patients treated with MTH in a univariate analysis, but not in a multivariate analysis. Increases or decreases of
NT-proBNP levels during MTH appear unrelated to 28 day mortality.
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Mild therapeutic hypothermia (MTH) is now considered
an established treatment to limit neurological injury and
improve survival in patients who have been successfully
resuscitated after cardiac arrest (CA) [1]. Despite the
introduction of MTH, the mortality rate in successfully
cardiopulmonary resuscitated patients after CA remains
high. In Europe, survival rates are only 9-23% after out of
hospital cardiac arrest [2]. Better prognostication is needed
to identify high and low risk patients and subsequently in-
tensify or reconsider treatment [3]. To date, no reliable
predictive marker for outcome after CA exists. Natriuretic
peptides, such as B-type natriuretic peptide (BNP) and
N-terminal proBNP (NT-proBNP), are useful markers for
diagnosis and prognosis of congestive heart failure and
other cardiovascular diseases. In 2007 it was shown that
BNP is of prognostic value in CA patients [4,5].
BNP and NT-proBNP are both end-stage products of
the proBNP hormone, which is predominantly produced
in the atrial and ventricular myocardium after transcrip-
tion of the natriuretic peptide precursor B (NPPB) gene
[6]. ProBNP is then enzymatically cleaved into BNP and
NT-proBNP, which are both secreted into the circulation
in an approximate 1:1 ratio. NT-proBNP is biologically in-
active, while BNP exerts various effects such as the induc-
tion of vasodilation, increased diuresis and natriuresis.
Ventricular wall-stress [6], hypoxia [7-9] and ischemia-
reperfusion induced inflammation [10,11], results in
production of NT-proBNP and BNP. Although BNP is
removed via receptor-binding and enzymatic cleavage,
clearance of NT-proBNP is dependent on renal secretion
[12]. Some studies show that cerebral ischemia also in-
duces release of NT-proBNP and BNP [13-15]. Despite
the influence of several CA-related events, such as hyp-
oxic brain injury, ischemia-reperfusion injury and renal
dysfunction after return of spontaneous circulation, on
the expression of NT-proBNP, it potentially holds add-
itional prognostic information in comparison to BNP.
In regard to pre-analytical and analytical conditions,
NT-proBNP has several advantages over BNP. NT-
proBNP is considerably more stable at room temperate
and current laboratory assays are highly sensitive and
specific [16]. Furthermore, all commercially available
NT-proBNP assays utilize the same set of antibodies,
which greatly simplifies intra-laboratory comparisons.
Due to its renal clearance, NT-proBNP also has a much
longer in-vivo half time than BNP (1–2 hours versus
20 minutes respectively), which reduces the influence of
specific time-frame sampling, but, is therefore less sensi-
tive for acute changes. Taken together, NT-proBNP may
has the potential to exceed the prognostic value of BNP.
In the current retrospective observational study the
prognostic value of NT-proBNP for survival of patients
who were admitted to the ICU for treatment with MTHafter CA, as well as the dynamics of NT-proBNP levels
during hypothermia were investigated.
Methods
Study population
Patients with return of spontaneous circulation after all
cause cardiac arrest, eligible for MTH treatment and ad-
mitted to the ICU of the VU University medical centre
(Amsterdam, the Netherlands) between January 2009
and March 2013 were included. Exclusion criteria were
cardiac arrest due to submersion or asphyxia, traumatic
brain injury, and <18 years of age. Patients were treated
according to a strict protocol of MTH which includes
the use of cooled saline intravenous infusion and non-
invasive surface cooling using body wraps (Medi-Therm,
Gaymar, USA). After admission to the ICU, body wraps
were placed around the patient’s body and cooling was
started immediately. An external temperature control
unit adjusts the temperature of the water circulating
through the body wraps. An esophageal temperature
probe was inserted for continuous temperature monitor-
ing and connected to the temperature control unit for
automated temperature feedback control. Blood samples
were taken according to the phase of cooling (induction,
maintenance and rewarming). The induction phase, till
target temperature of 32.5°C was reached, was followed
by the maintenance phase of 24 hours at a core tem-
perature of 32.5°C. Thereafter the patients were grad-
ually rewarmed to normothermic core temperature of
36.5°C at a rate of ≤ 0.5°C/hour. According to Dutch le-
gislation, no approval of the research ethics committee
is required for this standard treatment. The research
ethics committee METc VUmc approved the anonymous
use of the patient data for this retrospective study.
Data retrieval
Data were obtained from a prospective registry database
involving all patients at the ICU after CA treated with
MTH. Demographics (age and gender), pre-existing co-
morbidities (diabetes mellitus (DM), congestive heart
failure (CHF), cardiovascular disease history (CVD) and
renal insufficiency), arrest conditions (cause of arrest, lo-
cation, witnessed and ventricular fibrillation/tachycardia
(VF/VT) as the initial rhythm), laboratory parameters
(NT-proBNP, Troponin-T, Creatine Kinase Myoglobin
(CK-MB), Creatinine, Urea, Lactate and pH) and APACHE
II score were recorded in our patient data management
system for critical care (Metavision, iMDsoft®, Israël). Sur-
vival at 28 days after ICU discharge was obtained from the
patients hospital file.
NT-proBNP measurements
Blood samples were collected from arterial lines, as part
of standard care, on the following time points; 1) after
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maintenance phase, after reaching a target temperature
of 32.5°C 3) at the end of the maintenance phase, before
the initiation of rewarming 4) at the end of the rewarm-
ing phase (Figure 1). NT-proBNP plasma levels were
assessed on an ELECSYS 1010 bench top immunoassay
analyser (Roche Diagnostics, Almere, Netherlands).
Statistical analysis
Continuous data are presented as median and interquar-
tile range (25th to 75th percentile). Unpaired data were
compared using Mann–Whitney U-tests. A change in
paired data was detected using Wilcoxon matched-pairs
signed-rank test. Dichotomous data are presented as
counts and percentages, comparisons were made using
Fishers exact test.
After dividing patients into increasing NT-proBNP
quartiles, binary logistic regression was performed to as-
sess the prognostic value of NT-proBNP. To investigate
the independent prognostic value of NT-proBNP, add-
itional parameters were added to the regression model if
there appeared to be a differential distribution between
the survivors and non-survivors (defined as P < 0.20). Fi-
nally, a Receiver operating characteristic (ROC) curve
was constructed to determine an optimal cut-off value.
Repeated measures obtained in the same patient during
the different MTH phases were analysed by one-way re-
peated measures ANOVA and Bonferroni’s post-hoc cor-
rection to identify inter-phase NT-proBNP level changes.
P-values below 0.05 were considered as statistically
significant. Calculations were performed using SPSS 20
(IBM Corporation, New York, USA). Graphs were made




A total of 469 patients were admitted to the ICU for
post-CA MTH treatment between January 2009 and
August 2013. Of these patients, 150 met one or more of
the exclusion criteria. From the remaining 319 patients,
250 had NT-proBNP levels measured in the period be-
tween ICU admission and induction of MTH and were





Figure 1 NT-proBNP measurement time points. NT-proBNP levels were
prior to cooling 2) during the maintenance phase, after reaching a target t
the initiation of rewarming 4) at the end of the rewarming phase.into survivors and non-survivors (Table 1). During the
28 days following admission, 114 (46%) patients died.
The median age of non-survivors was significantly
higher compared to survivors (68 years; IQR 61–76 ver-
sus 61 years; IQR 53 – 70, P = 0.002). The percentage of
witnessed arrests, initial rhythm VF/VT and cardiac
cause of arrest in non-survivors was significantly lower
than in survivors. Non-survivors had significantly lower
initial body temperature, higher APACHE II score,
shorter length of stay and lower GCS score compared to
survivors. Survivors had lower NT-proBNP, creatinine,
Urea, and lactate levels upon ICU admission compared
to non-survivors (Table 2).
NT-proBNP and survival
Based on the NT-proBNP levels measured upon admis-
sion, patients were grouped into quartiles. The first
quartile consisted of patients with NT-proBNP levels
below 203 ng/l, the second quartile of patients with
values between 203 and 787 ng/l, the third quartile of
patients with values between 787 and 2807 ng/l and the
fourth quartile was populated by patients with levels
higher than 2807 ng/l. Using a univariate binary logistic
regression model, NT-proBNP levels of the 4th quartile
were associated with increased odds of death within
28 days post ICU admission (OR 3.6, 95% CI = 1.7 – 7.5)
(Table 3, Figure 2A). Also, survival rates were lower in
the increasing quartiles (log rank test for trend, P < 0.01;
Figure 3).
Adding age (P < 0.001), diabetes (P = 0.070), VF/VT
(P < 0.001) and cardiac cause of arrest (P < 0.01) to the
binary logistic regression as covariates resulted in loss of
the association between the upper NT-proBNP quartiles
and 28-day mortality (Table 3, Figure 2B). Witnessed ar-
rest was not considered as a covariate due to its unknown
effect on the resuscitation period. Also, APACHE II was
disregarded because it is not readily available immediately
upon ICU admission, but 24 hours later.
Receiver operating characteristic curve
The ROC curve (Figure 4) for baseline NT-proBNP
showed that the highest combined sensitivity and speci-
ficity to predict 28-day mortality, was achieved using a





measured at four different time points: 1) after admission to the ICU,
emperature of 32.5°C, 3) at the end of the maintenance phase, before
Table 1 Patient characteristics
Survivors Non-survivors
n = 136 (54%) n = 114 (46%)
Demographics
Age (years) 61 (53–70) 68 (61–75)*
Female, n (%) 36 (26) 36 (32)
Body weight (kg) 80 (70–90) 80 (70–88)
Body Mass Index 25 (23–28) 25 (23–28)
History of Illness
Diabetes, n (%) 11 (8) 21 (18)
CVD history, n (%) 59 (43) 58 (51)
Congestive heart failure, n (%) 19 (14) 22 (19)
Renal insufficiency, n (%) 10 (7) 14 (12)
Cardiac arrest conditions
Out of hospital cardiac arrest, n (%) 121 (89) 95 (83)
Witnessed arrest, n (%) 106 (78) 75 (66)*
Initial rhythm VF/VT, n (%) 97 (71) 51 (45)*
Cardiac Cause, n (%) 112 (82) 76 (67)*
In-hospital intervention/assessment
CAG, n (%) 73 (54) 56 (49)
PCI, n (%) 44 (32) 34 (30)
CABG, n (%) 5 (4) 1 (1)
APACHE II score 29 (24–34) 35 (29–39)*
ICU Length of stay (days) 7 (4–13) 4 (3–9)*
GCS on ICU discharge 14 (11–15) 3 (2–5)*
Mild Therapeutic Hypothermia
Initial body temperature (°C) 34.9 (34.2–35.6) 34.5 (33.9–35.2)*
Cooling speed (°C/hour) 0.6 (0.3–0.8) 0.5 (0.2–0.8)
Rewarming speed (°C/hour) 0.3 (0.2–0.3) 0.3 (0.2–0.3)
* = P < 0.05 for inter-group comparisons (Mann Whitney U-test for continuous data, Fisher’s Exact test for dichotomous data). CVD, Cardiovascular disease;
VF/VT, Ventricular Fibrillation/Tachycardia; CAG, Coronary Angiogram; APACHE, Acute Physiology and Chronic Health Evaluation; GCS, Glasgow Coma Score.
Table 2 Laboratory parameters upon ICU admission
Survivors Non-survivors
n = 136 (54%) n = 114 (46%)
NT-proBNP (ng/l) 567 (146–1813) 1448 (366–4623)*
Troponin-T (μg/l) 0.05 (0.02–0.17) 0.07 (0.03–0.41)
Troponin-T above 99th percentile (>0.014 μg/l) 79 % 89 %
CK (U/l) 360 (157–910) 259 (130–820)
MB (μg/l) 7.8 (5.0–33.1) 10.1 (5.8–45)
Urea (mmol/l) 7.1 (5.9–9.4) 8.5 (6.6–11.2)*
Creatinine (μmol/l) 89 (75–107) 104 (82–128)*
Lactate (mmol/l) 4.8 (2.3–8.3) 7.4 (4.4–11.6)*
pH (lowest value) 7.3 (7.2–7.3) 7.3 (7.2–7.3)
* = P < 0.05 for inter-group comparisons (Mann Whitney U-test). NT-proBNP, N-terminal pro Brain Natriuretic Peptide; CK, Creatine Kinase; MB, Myoglobin.
Smit et al. BMC Anesthesiology  (2015) 15:48 Page 4 of 9
Table 3 Binary logistic regression models for increasing NT-proBNP quartiles and mortality
Unadjusted Adjusted
Ba S.E.b Pc ORd Ba S.E.b Pc ORd
Quartile 1 (<203 ng/l) 1 1
Quartile 2 (203–787 ng/l) 0.519 0.372 0.163 1.7 0.090 0.417 0.829 1.1
Quartile 3 (787–2807 ng/l) 0.454 0.372 0.222 1.6 0.124 0.413 0.764 1.1
Quartile 4 (>2807 ng/l) 1.270 0.378 0.001 3.6 0.475 0.440 0.280 1.6
Age (years) 0.026 0.409 0.021 1.0
Diabetes Mellitus (1 = yes) 0.548 0.340 0.181 1.7
VF/VT as initial rhytm (1 = yes) −0.723 0.392 0.033 0.5











OR 1.7 (0.8 - 3.5)
OR 3.6 (1.7 - 7.5)








OR 1.1 (0.5 - 2.5)
OR 1.6 (0.7 - 3.8)
OR 1.1 (0.5 - 2.5)
B (Adjusted)
Figure 2 Odds ratios for 28-day mortality. Unadjusted (A) and
adjusted odds ratios (B) for 28-day mortality in increasing quartiles.
Adjusted odds ratios were calculated by correcting for age, diabetes
mellitus, ventricular fibrillation/tachycardia as the initial rhythms and
cardiac cause of arrest. Data are presented as OR (95% Confidence
Interval). Abbreviations: OR, Odds Ratio.
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(AUC) was 0.63. The positive predictive value (PPV) was
54% (chance of death within 28 days with a baseline NT-
proBNP value higher than 834 ng/l). The negative pre-
dictive value (NPV) was 62% (chance of survival with a
baseline NT-proBNP value lower than 834 ng/l). The
highest specificity of 99% was reached at a cut-off level
of 20101 ng/l, which was accompanied by a sensitivity of
10%. The corresponding PPV and NPV were 92% and
57%, respectively. Using NT-proBNP values obtained
during or after MTH did not improve prognostic per-
formance (data not shown).
Dynamics of NT-proBNP levels during mild therapeutic
hypothermia
From the 250 patients, 139 patients had sequential NT-
proBNP levels measured between the start of induction
and the end of the rewarming phase (Figure 1). Patients
who died during the induction, maintenance or rewarm-

















Figure 3 28 day survival curves. Patients with higher NT-proBNP
levels died earlier and more frequently than patients with lower
levels (log rank test for trend, P < 0.01).


























Figure 4 NT-proBNP ROC curve. An optimal sensitivity and
specificity of respectively 58% and 58% was reached with a baseline
NT-proBNP cut-off value of 834 ng/l. Corresponding positive and
negative predictive values were 54% and 62%, respectively. When
considering maximal specificity, a cut-off of 20101 ng/l yielded a
specificity of 99% and a sensitivity of 10%. PPV and NPV were 92%
and 57%, respectively. AUC 0.63 (95%CI 0.56 - 0.70; P < 0.0001).
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leaving 113 patients with NT-proBNP levels measured at
all time points. Two specific expression patterns were
observed over time; NT-proBNP levels either increased
or decreased. Based on the pattern present, patients
were grouped as being a Descender (n = 51) or an As-
cender (n = 62) (Table 4).
At the start of induction, median NT-proBNP levels of
Descenders were 1981 ng/l (IQR 483–4217) and main-
tained at that level during the induction phase. At the
end of the maintenance phase NT-proBNP levels signifi-
cantly decreased compared to start of the maintenance
phase and reached even significantly lower levels at the
end of the rewarming phase. In the Ascenders group
NT-proBNP levels increased significantly during the in-
duction phase and further increased towards the end of
the maintenance phase. During the rewarming phase
NT-proBNP levels did not change compared to the end
of the maintenance phase.
In comparison, Ascenders started with significantly
lower NT-proBNP levels than Descenders at the start of
the induction. This difference persisted until the end of
the induction phase and was lost after the maintenance
phase. Other than NT-proBNP, only the average systolic
blood pressure during the induction phase was different
between groups (Table 4). Ascenders had a significantly
lower systolic blood pressure than Descenders. During
the maintenance phase however, both lactate levels andleukocyte counts were higher in the Ascender group,
compared to the Descender group. Lactate levels
remained higher during the rewarming phase in the As-
cender group compared to the Descender group. Other
parameters, such as PaO2, sO2, heart rate, diastolic
blood pressure and noradrenaline use was comparable
between both groups during all phases of MTH. Add-
itionally, the number of deaths in the Ascender and the
Descender group did not differ significantly.
Discussion
The present study shows that NT-proBNP levels upon
ICU admission in cardiopulmonary resuscitated patients
are positively associated with death within 28 days fol-
lowing the initial insult. Irrespective of other prognostic
data, patients scaled into the 4th NT-proBNP quartile
had higher odds of dying, compared to patients in the
lowest quartile. When adjusted for co-morbidities and
arrest conditions however, statistical significance was
lost. As an independent prognostic marker NT-proBNP
achieved a mediocre optimal sensitivity and specificity of
58% with a cut-off value of 834 ng/l. With our study
population, this translates into a negative predictive
value of 62% and a positive predictive value of 54%. Al-
ternatively, when one seeks to optimize specificity (cut-
off at 20101 ng/l), NT-proBNP produced a PPV of 92%
with a persistent low NPV at 57%. Due to the high
spread in NT-proBNP levels, we think that measuring
NT-proBNP at the ICU, utilizing either cut-off, is of lit-
tle value for the prediction of outcome.
To our knowledge, this is the first study to evaluate
the prognostic value of NT-proBNP in post-CA patients,
treated with MTH. However, a study by Nagao et al.
assessed the resuscitative value of BNP in post-CA pa-
tients treated with MTH [5]. Similarly, they established a
positive relationship between higher BNP levels on ad-
mission at the emergency room and unfavourable out-
come. Using a BNP cut off value of 80 pg/ml, they were
able to predict an unfavourable neurological outcome
with a sensitivity of 84% and a specificity of 89%. Their
secondary endpoint survival to hospital discharge de-
creased in stepwise fashion across the increasing quar-
tiles of BNP level. These results were later on confirmed
by Sodeck et al., showing BNP levels on admission to
the emergency room predict neurological outcome and
also survival at 6 months after CA [4]. As compared to
our current investigation however, BNP performed better
as an independent prognostic biomarker, as indicated by a
higher sensitivity and specificity and a persisting signifi-
cant odds ratio after multivariate regression analysis.
The above findings counter our hypothesis that NT-
proBNP is of superior prognostic value in comparison to
BNP. Several important differences should be noted.
Fore one, we assessed 28-day mortality as a primary
Table 4 MTH phases
Descender Ascender
n = 51 (45%) n = 62 (55%)
Died (n) 21 (41%) 23 (37%)
NT-proBNP
NT-proBNP, start induction (ng/l) 1981 (483–4217) 303 (116–1331)*†
NT-proBNP, start maintenance (ng/l) 2011 (720–4239)† 588 (213–1710)*†
NT-proBNP, end maintenance (ng/l) 1297 (454–3761)† 1591 (476–3448)
NT-proBNP, end rewarming (ng/l) 747 (287–2037) 1681 (472–3383)
Induction phase
paO2 (mmHg) 96 (75–129) 88 (72–111)
sO2 (%) 97 (93–99) 97 (93–99)
Lactate (μgl/L) 2.0 (1.2–2.6) 2.5 (1.4–4.4)
Leukocyte count (10^9/L) 14.0 (11.3–18.5) 17.7 (12.3–21.8)
Heart Rate (bpm) 68 (58–76) 73 (59–91)
Systolic blood pressure (mmHg) 114 (104–129) 106 (100–117)*
Diastolic blood pressure (mmHg) 60 (57–68) 62 (54–69)
Noradrenaline (mg) 0.44 (0.02–1.15) 0.39 (0.08–1.11)
Diuresis (ml/hour) 74 (34–144) 67 (35–150)
Maintenance phase
paO2 (mmHg) 86 (73–112) 88 (73–107)
sO2 (%) 97 (94–99) 96 (94–98)
Lactate (μgl/L) 1.4 (1.0–2.2) 2.1 (1.4–3.4)*
Leukocyte count (10^9/L) 10.4 (7.6–13.6) 13.0 (9.8–16.6)*
Heart Rate (bpm) 57 (48–66) 61 (50–71)
Systolic blood pressure (mmHg) 109 (104–117) 105 (101–111)
Diastolic blood pressure (mmHg) 57 (53–60) 57 (53–62)
Noradrenaline (mg) 0.61 (0.23–1.20) 0.60 (0.15–1.19)
Diuresis (ml/hour) 77 (44–123) 72 (34–116)
Rewarming phase
paO2 (mmHg) 85 (74–100) 88 (76–102)
sO2 (%) 97 (95–98) 97 (93–98)
Lactate (μgl/L) 1.3 (0.9–2.1) 2.0 (1.5–2.8)*
Leukocyte count (10^9/L) 10.4 (7.5–15.2) 11.1 (9.2–16.3)
Heart Rate (bpm) 72 (63–85) 75 (66–86)
Systolic blood pressure (mmHg) 108 (100–115) 109 (100–119)
Diastolic blood pressure (mmHg) 55 (52–59) 55 (51–59)
Noradrenaline (mg) 0.81 (0.11–1.29) 0.61 (0.17–1.60)
Diuresis (ml/hour) 42 (30–68) 38 (21–86)
NT-proBNP, start induction; values measured between ICU admission and the start of cooling. NT-proBNP, start maintenance; the first value measured after reaching
target temperature (32°C). NT-proBNP, end maintenance; the last value measured before initiation of the warming phase. NT-proBNP end-rewarming; the first value
measured after reaching target temperature (36,5°C). * = P < 0.05 for inter-group comparisons (Mann Whitney U-test). † = P < 0.05 for intra-group comparison to the
consecutive phase. MTH, mild therapeutic hypothermia; NT-proBNP, N-terminal pro Brain Natriuretic Peptide; ICU, Intensive Care Unit.
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neurological outcome and survival to hospital discharge
or in a period of six months. More importantly, we mea-
sured NT-proBNP levels upon admission to the ICU,while BNP levels were determined upon arrival at the
emergency department. The latter is possibly of special
importance, because patients most likely have received
therapeutic interventions that can influence NT-proBNP
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sion of cold saline at the emergency department as a
preparation to MTH at the ICU.
Therapeutic intervention in itself, such as intravenous
administration of fluids, oxygenation and vasopressors
can influence BNP gene expression. The infusion of sa-
line increases BNP transcription, without affecting blood
pressure or heart rate [17]. Although the authors did not
provide an explanation for this phenomenon, it is likely
that infusion leads to increased ventricular expansion
and subsequent synthesis of BNP. Additionally, infusion
of fluids may lead to hemodilution, causing relative
hypoxia. This is the opposite of one of the suggested
biological functions of BNP, which is to facilitate hemo-
concentration in order to increase the per volume oxy-
gen carrying capacity of blood in response to hypoxia
[18]. In contrast, the opposite of hypoxia, a higher than
normal partial oxygen pressure, hyperoxia, may also
cause elevation of NT-proBNP levels in-vivo [19]. Sup-
plemental oxygen is often administered during cardio-
pulmonary resuscitation and a high PaO2 is no rare
phenomenon, especially in mechanically ventilated pa-
tients [20-22]. In regard to vasopressor therapy, in-vitro
experiments show that human cardiomyocytes synthesize
BNP upon stimulation with either dobutamine, epineph-
rine or norepinephrine [23]. The BNP measurements in
the study of Nagao et al. were all performed before ad-
ministration of epinephrine [5].
Even though we cannot confirm that the abovemen-
tioned interventions actually cause a cumulative increase
of NT-proBNP in post-CA patients, thereby possibly re-
ducing prognostic performance, it warrants attention to-
wards the application of NT-proBNP as a prognostic
marker in an ICU setting. For future studies, it would
therefore be interesting to acquire blood samples for
NT-proBNP testing as early as possible, right after re-
turn of spontaneous circulation or at arrival at the emer-
gency department and re-evaluate its prognostic value.
Dynamics of NT-proBNP levels during mild therapeutic
hypothermia
To the best of our knowledge this is the first study with
repeated measurement of NT-proBNP plasma levels in
post-CA patients. During MTH treatment, two types of
responses where observed. NT-proBNP levels increased
(Ascenders) or decreased (Descenders) over the course
of MTH.
Descenders were admitted to the ICU with a signifi-
cantly higher NT-proBNP value than Ascenders. In the
case of NT-proBNP decrease in time, we saw that levels
continue to drop even after rewarming. In the Ascender
group however, the rise of NT-proBNP had stopped at
the end of the maintenance phase. Interestingly, the dif-
ferences between Ascenders and Descenders, in regardto NT-proBNP levels, were completely lost at the end of
the maintenance phase. This may indicate that the appli-
cation of hypothermia imposes a similar state in all
patients. Which for some patients means relieve (NT-
proBNP levels decrease), while in others MTH may
actually cause stress (NT-proBNP levels increase). In ac-
cordance, MTH is currently applied as a one-size fits all
therapy, with a target temperature of 32.5°C for all pa-
tients. The increase of NT-proBNP levels in the As-
cender group could also be due to an insufficient control
of inflammation, relative to the Descender group.
Although there was insufficient inflammation related
data available to properly investigate this relationship,
leukocyte counts did appear to be higher overall in the As-
cender group. Ultimately, the different responses did not
appear to affect outcome. In other words, an increase or
decrease of NT-proBNP levels was not associated with 28-
day mortality. Overall, we see the response-heterogeneity
in patients treated with MTH as a confirmation that ther-
apy induced changes in NT-proBNP levels do not neces-
sarily reflect severity of illness, indicated by a lack of
association with 28-day mortality, and thereby reduce
overall sensitivity and specificity of NT-proBNP as pre-
dictive marker.
Study limitations
The small study population is one of the limitations of
the current study. Implementation of age adjusted cut-
off values might improve the predictive performance of
NT-proBNP, but this requires a considerably larger sam-
ple size. Mortality as an endpoint might also be consid-
ered inadequate, since survival does not guarantee a
subsequent satisfactory quality of life. A quality of life
questionnaire or inclusion of a cerebral performance cat-
egory score on hospital discharge in a prospective
follow-up study would address this issue.
This was a retrospective study and not all patients had
sequential NT-proBNP levels measured. As often with
retrospective studies, it is difficult to determine why
these measurements were omitted in these particular pa-
tients and as a result may have caused selection bias in
our analysis.
Additionally, the data used in this analysis were gathered
prior to the publication by Nielsen et al., who compared
different target temperatures [24]. Our ICU only applies a
target temperature of 32.5°C and therefore the dynamics
of NT-proBNP during MTH reported here cannot be ex-
trapolated to treatment with a higher target temperature
without confirmation in an additional study.
Since measurements were done at the ICU, thera-
peutic interventions at the emergency department, such
as fluid infusions and vasopressor therapy, may have
siginificantly influenced the prognosticating ability of
NT-proBNP.
Smit et al. BMC Anesthesiology  (2015) 15:48 Page 9 of 9Conclusions
High NT-proBNP plasma concentrations on ICU admis-
sion are associated with high 28-day mortality in post-
CA patients treated with MTH in a univariate analysis.
However, when considering age, presence of diabetes,
VF/VT and cause of cardiac arrest in a multivariate ana-
lysis, NT-proBNP offers no additional prognostic infor-
mation. During MTH, an overall increase or decrease of
NT-proBNP levels was observed, which appear to be un-
related to 28-day mortality.
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